
MRVI
Maravai LifeSciences Holdings Inc.
$2.75
+$0.05(+1.85%)
18
Overall
--
Value
18
Tech
--
Quality
Market Cap
$738.00M
Volume
1.16M
52W Range
$1.67 - $8.60
Target Price
$4.39
Order:
Income Statement
Metric | Trend | Chart | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
---|---|---|---|---|---|---|
REVENUE | ||||||
Total Revenue | $799.2M | $883.0M | $288.9M | $259.2M | ||
Total Revenue | $799.2M | $883.0M | $288.9M | $259.2M | ||
COST OF GOODS SOLD | ||||||
Cost of Revenue | $140.6M | $169.0M | $148.7M | $150.9M | ||
GROSS PROFIT | ||||||
Gross Profit | $658.7M | $714.0M | $140.2M | $108.3M | ||
OPERATING EXPENSES | ||||||
Operating Expenses | $255.8M | $147.6M | $-500.2M | $181.0M | ||
Research & Development | $15.2M | $18.4M | $17.3M | $19.2M | ||
Research Expense | $15.2M | $18.4M | $17.3M | $19.2M | ||
Selling, General & Administrative | $100.1M | $129.3M | $-517.5M | $161.8M | ||
Selling & Marketing Expenses | $1.3M | $2.5M | $2.9M | $3.5M | ||
General & Administrative Expenses | $100.1M | $129.3M | $-517.5M | $161.8M | ||
Promotion & Advertising | $1.3M | -- | -- | -- | ||
Salaries & Wages | -- | $18.7M | $34.6M | $40.0K | ||
Depreciation & Amortization | $140.6M | $7.6M | $12.9M | $20.9M | ||
Depreciation & Amortization | $140.6M | $7.6M | $12.9M | $20.9M | ||
Amortization | $140.6M | $307.9M | $353.4M | $222.5M | ||
Other Operating Expenses | $-232.0K | -- | -- | -- | ||
OPERATING INCOME | ||||||
Operating income | $554.6M | $574.2M | $-31.6M | $-235.6M | ||
EBITDA | $597.2M | $612.8M | $712.4M | $-154.0M | ||
NON-OPERATING ITEMS | ||||||
Interest Expense (Non-Operating) | $30.3M | $20.4M | $45.9M | $47.7M | ||
Intinc | -- | $2.3M | $27.7M | $27.4M | ||
Net Non-Operating Interest Income/Expense | $-30.3M | $-18.1M | $-18.2M | $-20.3M | ||
Other Income/Expense | $-11.5M | $3.1M | $-1.9M | $3.5M | ||
Other Special Charges | $279.0K | $-566.0K | $-1.3M | $-5.5M | ||
SPECIAL ITEMS | ||||||
Restructring And Mn A Income | -- | -- | $6.5M | $-1.2M | ||
Special Income Charges | -- | $-4.1M | $-6.5M | $-164.9M | ||
Impairment of Capital Assets | -- | -- | -- | $166.2M | ||
PRE-TAX INCOME | ||||||
EBIT | $561.0M | $571.9M | $663.6M | $-213.8M | ||
Pre-Tax Income | $530.8M | $551.5M | $617.7M | $-261.5M | ||
INCOME TAX | ||||||
Tax Provision | $61.5M | $60.8M | $756.1M | $-1.9M | ||
NET INCOME | ||||||
Net Income | $182.0M | $220.2M | $-119.0M | $-144.8M | ||
Net Income (Continuing Operations) | $182.0M | $490.7M | $-138.4M | $-259.6M | ||
Net Income (Discontinued Operations) | $182.0M | $220.2M | $-119.0M | $-144.8M | ||
Net Income (Common Stockholders) | $182.0M | $220.2M | $-119.0M | $-144.8M | ||
TOTALS | ||||||
Total Expenses | $396.4M | $316.6M | $-351.5M | $331.9M | ||
SHARE & EPS DATA | ||||||
Average Shares Outstanding | $114.8M | $131.5M | $131.9M | $137.9M | ||
Average Shares Outstanding (Diluted) | $257.8M | $255.3M | $131.9M | $137.9M | ||
Shares Outstanding | $255.2M | $250.9M | $251.4M | $254.3M | ||
Basic EPS | $1.59 | $1.67 | $-0.90 | $-1.05 | ||
Basic EPS (Continuing Operations) | $1.59 | $1.67 | $-0.90 | $-1.05 | ||
Diluted EPS | $1.56 | $1.67 | $-0.90 | $-1.05 | ||
Diluted EPS (Continuing Operations) | $1.56 | $1.67 | $-0.90 | $-1.05 | ||
OTHER METRICS | ||||||
Acquisition Expense | $1.5M | $2.4M | $4.4M | $1.7M | ||
Gain On Sale Of Business | $11.2M | -- | -- | -- | ||
Insurance And Claims | -- | -- | $-668.9M | -- | ||
Minority Interests | $-287.2M | $-270.5M | $19.3M | $114.8M | ||
Other Gand A | $100.1M | $129.3M | $-517.5M | $161.8M | ||
Write Down | -- | $4.1M | -- | -- | ||
Restruct | -- | -- | $6.5M | $-1.2M |
Financial data is updated quarterly and may not reflect the most recent earnings.
A | B | C | D | |
---|---|---|---|---|
1 | Symbol | Price | Change | Vol |
2 | MRVI | $2.75 | +1.9% | 1.16M |
3 | ||||
4 | ||||
5 | ||||
6 |
Get Maravai LifeSciences Holdings Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW